Literature DB >> 16314946

Tumor growth, invasion, and angiogenesis in malignant gliomas.

Eric T Wong1.   

Abstract

Entities:  

Mesh:

Year:  2005        PMID: 16314946     DOI: 10.1007/s11060-005-9042-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  5 in total

Review 1.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.

Authors:  H A Fine; W D Figg; K Jaeckle; P Y Wen; A P Kyritsis; J S Loeffler; V A Levin; P M Black; R Kaplan; J M Pluda; W K Yung
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 3.  Delivery systems and molecular targets of mechanism-based therapies for GBM.

Authors:  Surasak Phuphanich; Daniel J Brat; Jeffrey J Olson
Journal:  Expert Rev Neurother       Date:  2004-07       Impact factor: 4.618

4.  Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.

Authors:  Morris D Groves; Vinay K Puduvalli; Kenneth R Hess; Kurt A Jaeckle; Pamela Peterson; W K Alfred Yung; Victor A Levin
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

5.  Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.

Authors:  G M Marx; N Pavlakis; S McCowatt; F M Boyle; J A Levi; D R Bell; R Cook; M Biggs; N Little; H R Wheeler
Journal:  J Neurooncol       Date:  2001-08       Impact factor: 4.130

  5 in total
  4 in total

1.  Metabolomics of human cerebrospinal fluid identifies signatures of malignant glioma.

Authors:  Jason W Locasale; Tamar Melman; Susan Song; Xuemei Yang; Kenneth D Swanson; Lewis C Cantley; Eric T Wong; John M Asara
Journal:  Mol Cell Proteomics       Date:  2012-01-12       Impact factor: 5.911

2.  Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.

Authors:  Eric T Wong; Joshua Timmons; Amy Callahan; Lauren O'Loughlin; Bridget Giarusso; David C Alsop
Journal:  BMC Cancer       Date:  2016-11-22       Impact factor: 4.430

3.  Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma.

Authors:  Edwin Lok; Pyay San; Van Hua; Melissa Phung; Eric T Wong
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

4.  Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas.

Authors:  Eric T Wong; David Alsop; Diana Lee; Angela Tam; Loretta Barron; Julianne Bloom; Shiva Gautam; Julian K Wu
Journal:  Cerebrospinal Fluid Res       Date:  2008-01-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.